Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: KRAS Activating Mutation Clear all
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumor, B-Raf Mutation-Related Tumors
Interventions
BGB-3245
Drug
Lead sponsor
MapKure, LLC
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
Beverly Hills, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced May 21, 2026, 7:22 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease
Interventions
avutometinib (VS-6766) and adagrasib
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced May 21, 2026, 7:22 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
Interventions
S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Gilbert, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous)
Interventions
IMM-6-415
Drug
Lead sponsor
Immuneering Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Scottsdale, Arizona • Duarte, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced May 21, 2026, 7:22 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas
Interventions
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
ERAS-007, Encorafenib, Cetuximab, Palbociclib
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Duarte, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Non-squamous Non-small-cell Lung Cancer
Interventions
ERAS-007, ERAS-601, Osimertinib, Sotorasib
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Duarte, California • Orange, California • Santa Monica, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced May 21, 2026, 7:22 PM EDT
Available No phase listed Expanded access
View directory record Official record
Conditions
Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma, Non Small Cell Lung Cancer, Thyroid Cancer, Bladder Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer, Cholangiocarcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, MAPK Gene Mutation, KRAS Activating Mutation, BRAF Gene Mutation, NRAS Gene Mutation, HRAS Gene Mutation, MEK Mutation, ERK Mutation
Interventions
Ulixertinib (BVD-523)
Drug
Lead sponsor
xCures
Industry
Eligibility
12 Years and older
U.S. locations
27
States / cities
Huntsville, Alabama • Mobile, Alabama • Arroyo Grande, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced May 21, 2026, 7:22 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Non Small Cell Lung Cancer, KRAS Activating Mutation
Interventions
avutometinib and sotorasib, avutometinib and sotorasib and defactinib
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Boulder, Colorado • Washington D.C., District of Columbia • Arlington Heights, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced May 21, 2026, 7:22 PM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions
Selumetinib, Docetaxel, Placebo, Pegylated G-CSF
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
17
States / cities
Aurora, Colorado • Pembroke Pines, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Non Small Cell Lung Cancer, KRAS Activating Mutation
Interventions
avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
28
States / cities
Duarte, California • Aurora, Colorado • Lone Tree, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced May 21, 2026, 7:22 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer, PD-L1 Gene Mutation, KRAS Activating Mutation
Interventions
Durvalumab, Carboplatin, Pemetrexed
Drug
Lead sponsor
Shirish M Gadgeel
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced May 21, 2026, 7:22 PM EDT